Compare › semaglutide vs tirzepatide
semaglutide vs tirzepatide
Both semaglutide and tirzepatide are approved in the US, so the useful differences between them are which conditions each is approved for and what is still under study. semaglutide has 405 trials on file here and tirzepatide 139, which is a rough measure of how far each programme has been pushed.
A side-by-side of what the public record holds on each: regulatory status in the US and EU, how much trial work is running, and which conditions each is being studied in. No efficacy comparison: head-to-head claims belong to the trials that made them, not to us.
| semaglutide | tirzepatide | |
|---|---|---|
| Status | marketed | marketed |
| Target | GLP-1 | GIP/GLP-1 |
| Route | SC/oral | SC |
| Sponsor | Novo Nordisk | Eli Lilly |
| US brand names | OZEMPIC, RYBELSUS, WEGOVY, WEGOVY FLEXTOUCH, WEGOVY HD | MOUNJARO, MOUNJARO (AUTOINJECTOR), MOUNJARO KWIKPEN, ZEPBOUND, ZEPBOUND (AUTOINJECTOR), ZEPBOUND KWIKPEN |
| First FDA approval | 2017-12-05 | 2022-05-13 |
| EU authorisation | Ozempic, Rybelsus, Wegovy | Mounjaro |
| FDA actions on file | 51 | 27 |
| Active trials | 203 | 99 |
| Active phase 3 | 72 | 20 |
| Participants enrolled | 94,274 | 43,561 |
| Results scheduled | 76 | 34 |
| Supply records | 3 | 0 |
Where they are being studied
Both: Alcohol use disorder; Atrial fibrillation; Cancer; Cardiovascular disease; Chronic kidney disease; Diabetes (unspecified); Heart failure; Hypertension; MASH / NAFLD; Metabolic syndrome; Obesity & overweight; Obstructive sleep apnea; Polycystic ovary syndrome; Prediabetes; Psychiatric conditions; Substance use; Type 1 diabetes; Type 2 diabetes
semaglutide only: Diabetic kidney disease; Neurodegenerative disease
tirzepatide only: Osteoarthritis